Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction.
Angela C RiegerBryon A TompkinsMakoto NatsumedaVictoria FloreaMonisha N BanerjeeJose RodriguezMarcos RosadoValeria PorrasKrystalenia ValasakiLauro M TakeuchiKevin CollonSohil DesaiMichael A BellioAisha KhanNilesh D KashikarAna Marie LandinDarrell V HardinDaniel A RodriguezWayne BalkanJoshua M HareIvonne Hernandez SchulmanPublished in: Stem cells translational medicine (2022)
Intra-renal artery allogeneic cell therapy was safe in a CKD swine model manifesting the characteristics of HFpEF. The beneficial effect on renal function and ventricular compliance in the ACCT group supports further research of cell therapy for cardiorenal syndrome.
Keyphrases
- cell therapy
- chronic kidney disease
- combination therapy
- stem cell transplantation
- stem cells
- bone marrow
- mesenchymal stem cells
- end stage renal disease
- single cell
- heart failure
- left ventricular
- high glucose
- hematopoietic stem cell
- case report
- diabetic rats
- high dose
- atrial fibrillation
- catheter ablation
- stress induced